+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Biosimilar Monoclonal Antibodies Market by Antibody Class, Molecule Class, Dosage Form, Treatment Type, Therapeutic Area, End User - Global Forecast 2026-2032- Product Image
Biosimilar Monoclonal Antibodies Market by Antibody Class, Molecule Class, Dosage Form, Treatment Type, Therapeutic Area, End User - Global Forecast 2026-2032- Product Image
Sale

Biosimilar Monoclonal Antibodies Market by Antibody Class, Molecule Class, Dosage Form, Treatment Type, Therapeutic Area, End User - Global Forecast 2026-2032

  • Report

  • 197 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 6010903
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Biosimilar Monoclonal Antibodies Market is projected to reach USD 9.91 Billion in 2026. It is expected to continue growing at a CAGR of 11.49%, reaching USD 19.05 Billion by 2032.

Biosimilar monoclonal antibodies are moving from a cost-containment option to a core pillar of biologic therapy access across oncology, immunology, ophthalmology, and inflammatory diseases. These products are approved through rigorous comparability pathways requiring analytical, nonclinical, pharmacokinetic, immunogenicity, and clinical evidence showing no clinically meaningful differences from reference biologics in safety, purity, and potency.

The market is shaped by patent expirations for high-revenue biologics, increasing payer pressure, and expanding physician confidence as real-world evidence accumulates. Regulatory precedents from the FDA, EMA, WHO, and national agencies have strengthened trust in biosimilar monoclonal antibodies, while hospital formularies and specialty pharmacy channels are accelerating adoption where procurement systems reward value-based competition.

Transformative Shifts Reshaping Biosimilar Monoclonal Antibodies

The competitive landscape is undergoing a structural shift as biosimilar monoclonal antibodies expand beyond early infliximab, trastuzumab, rituximab, and bevacizumab categories into broader immunology and ophthalmology opportunities. The U.S. entry of multiple adalimumab biosimilars in 2023 marked a pivotal access milestone, reinforcing that payer contracting, interchangeability decisions, formulary placement, and channel strategy can be as important as regulatory approval.

Manufacturers are responding with more efficient cell-line development, advanced analytics, high-concentration formulations, citrate-free presentations, and device differentiation. At the same time, health systems are tightening evidence expectations around switching, extrapolation of indications, immunogenicity, pharmacovigilance, and supply reliability, making manufacturing quality and post-market data central competitive differentiators.

Cumulative Impact of Artificial Intelligence on Biosimilar Development

Artificial intelligence is cumulatively improving the biosimilar monoclonal antibody value chain by accelerating candidate characterization, predicting critical quality attributes, optimizing cell-culture parameters, and supporting comparability assessments. Machine learning models are increasingly used to interpret high-dimensional analytical data from glycosylation, charge variants, aggregation, binding affinity, and potency assays, helping teams identify variability earlier in development.

AI also supports regulatory intelligence, pharmacovigilance signal detection, literature surveillance, demand planning, and market access strategy. However, adoption remains bounded by validation, data integrity, model explainability, cybersecurity, and regulatory documentation requirements. The most credible near-term impact is not replacing biosimilar evidence generation, but reducing development risk, improving manufacturing consistency, and strengthening post-launch monitoring.

Key Regional Insights Across Global Biosimilar Monoclonal Antibody Markets

Asia-Pacific is emerging as a strategic biosimilar monoclonal antibodies hub, supported by biologics manufacturing capacity in China, India, South Korea, and Japan, along with rising demand for affordable oncology, autoimmune, and ophthalmology therapies. Regulatory reforms across the region, including biosimilar guidelines aligned with international comparability principles, are improving confidence while local production policies help address affordability and supply continuity.

North America remains highly influenced by payer contracting, FDA biosimilar and interchangeable designations, reimbursement design, and specialty pharmacy dynamics, with the United States driving commercial complexity and Canada emphasizing provincial switching policies. Latin America is advancing through procurement-led access models, reliance pathways, and regulatory convergence, with Brazil and Mexico playing important roles in public health purchasing and biosimilar policy development.

Europe remains the most mature adoption environment, supported by EMA experience, national tendering systems, physician familiarity with biosimilar switching, and extensive real-world evidence in immunology and oncology. The Middle East, especially GCC markets, is expanding biologics access through public-sector investment, hospital modernization, and national health transformation programs, while Africa shows long-term potential where cold-chain infrastructure, pricing, local regulatory capacity, and procurement financing continue to shape uptake.

Key Group Insights for ASEAN, GCC, EU, BRICS, G7, and NATO Markets

ASEAN markets are prioritizing affordability, regulatory capacity building, and local manufacturing partnerships as demand rises for oncology and immunology biologics. Countries in the region are increasingly using national reimbursement lists, hospital tenders, and technology transfer collaborations to improve access while maintaining pharmacovigilance requirements for complex biologics.

The GCC is using centralized purchasing, hospital modernization, and national health transformation programs to expand biosimilar access, particularly in Saudi Arabia and the United Arab Emirates. The European Union remains the benchmark for biosimilar policy maturity, with centralized EMA evaluation, national substitution or switching frameworks, and country-level tendering driving competition and physician acceptance.

BRICS economies are strategically important because China, India, Brazil, and Russia combine large patient populations with domestic biologics ambitions, while South Africa’s access priorities highlight the need for affordability and reliable supply. G7 markets offer strong regulatory predictability and reimbursement sophistication, and NATO members in Europe and North America are increasingly focused on medicine supply resilience, biologic affordability, and secure pharmaceutical manufacturing networks.

Key Country Insights in Major Biosimilar Monoclonal Antibody Markets

The United States is a major commercial opportunity shaped by FDA approvals, interchangeable biosimilar designations, reimbursement design, pharmacy benefit management, and provider-administered buy-and-bill economics. Canada continues to promote biosimilar use through provincial reimbursement and switching policies, while Mexico and Brazil use public procurement, regulatory modernization, and institutional purchasing to broaden biologic access.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from established biosimilar prescribing experience, although tendering, physician autonomy, substitution policy, and payer incentives vary by country. Russia has emphasized domestic biologics production and import substitution policies, while China and India combine large treatment-naïve populations with expanding biosimilar manufacturing capacity, improving access to monoclonal antibody therapies across oncology and inflammatory diseases.

Japan maintains stringent regulatory standards and a cautious but evidence-based adoption environment, while South Korea is recognized as a major global biosimilar manufacturing base supported by advanced biologics infrastructure and regulatory experience. Australia supports uptake through reimbursement policy, reference pricing mechanisms, and clinician education, making it an important developed Asia-Pacific market for evidence-based biosimilar adoption.

Actionable Recommendations for Biosimilar Monoclonal Antibody Leaders

Industry leaders should prioritize portfolios aligned with high-value biologic patent expirations, clear differentiation in formulation or delivery, and strong supply reliability. Commercial success requires early payer engagement, robust health economic evidence, switching education, transparent immunogenicity communication, and pharmacovigilance programs that build confidence among prescribers, pharmacists, and patients.

Organizations should invest in advanced analytics, quality-by-design manufacturing, and real-world evidence platforms to demonstrate consistency beyond approval. Partnerships with hospitals, specialty pharmacies, government procurement agencies, and local manufacturers can improve market entry, particularly in price-sensitive regions where tender performance, cold-chain readiness, and access commitments determine scale.

Research Methodology for Evidence-Based Market Assessment

This executive summary is developed using a structured secondary research approach grounded in publicly available regulatory, clinical, policy, and market-access evidence. Core references include biosimilar guidance and approval databases from the FDA, EMA, WHO, national regulatory authorities, public procurement frameworks, peer-reviewed literature, clinical trial registries, pharmacovigilance resources, and recognized healthcare policy sources.

The methodology emphasizes triangulation across regulatory approvals, patent and exclusivity events, payer policy trends, therapeutic adoption patterns, switching guidance, and manufacturing capabilities. Insights were assessed for relevance to monoclonal antibody biosimilars, with preference for verifiable evidence over promotional claims and a focus on commercially actionable trends without relying on market sizing, market share, or forecasting assumptions.

Conclusion: Biosimilar Monoclonal Antibodies Enter a Scaled Access Era

Biosimilar monoclonal antibodies are becoming essential to sustainable biologic care as health systems seek to reduce costs while preserving clinical outcomes. The market is no longer defined only by approval counts; it is increasingly driven by interchangeability, contracting strategy, physician confidence, real-world evidence, pharmacovigilance, and manufacturing excellence.

Organizations that combine scientific rigor with agile market access execution will be best positioned to strengthen adoption. As AI-enabled analytics, regulatory maturity, and global procurement reforms advance, biosimilar monoclonal antibodies are expected to play a larger role in expanding patient access to high-value biologic therapies.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Biosimilar Monoclonal Antibodies Market, by Antibody Class
7.1. Chimeric Monoclonal Antibodies
7.2. Humanized Monoclonal Antibodies
8. Biosimilar Monoclonal Antibodies Market, by Molecule Class
8.1. Adalimumab
8.2. Infliximab
8.3. Rituximab
8.4. Trastuzumab
8.5. Bevacizumab
8.6. Ranibizumab
9. Biosimilar Monoclonal Antibodies Market, by Dosage Form
9.1. Liquid Solution
9.2. Lyophilized Powder
9.3. Prefilled Syringe
10. Biosimilar Monoclonal Antibodies Market, by Treatment Type
10.1. Monotherapy
10.2. Combination Therapy
11. Biosimilar Monoclonal Antibodies Market, by Therapeutic Area
11.1. Immunology
11.2. Oncology
11.3. Ophthalmology
11.4. Rheumatology
11.5. Autoimmune & Inflammatory Diseases
12. Biosimilar Monoclonal Antibodies Market, by End User
12.1. Specialty Clinics
12.2. Hospitals
12.3. Home Healthcare
13. North America Biosimilar Monoclonal Antibodies Market
14. Europe Biosimilar Monoclonal Antibodies Market
15. Asia-Pacific Biosimilar Monoclonal Antibodies Market
16. Latin America Biosimilar Monoclonal Antibodies Market
17. Africa Biosimilar Monoclonal Antibodies Market
18. Middle East Biosimilar Monoclonal Antibodies Market
19. NATO Biosimilar Monoclonal Antibodies Market
20. G7 Biosimilar Monoclonal Antibodies Market
21. European Union Biosimilar Monoclonal Antibodies Market
22. BRICS Biosimilar Monoclonal Antibodies Market
23. ASEAN Biosimilar Monoclonal Antibodies Market
24. GCC Biosimilar Monoclonal Antibodies Market
25. United States Biosimilar Monoclonal Antibodies Market
26. China Biosimilar Monoclonal Antibodies Market
27. Canada Biosimilar Monoclonal Antibodies Market
28. Germany Biosimilar Monoclonal Antibodies Market
29. Brazil Biosimilar Monoclonal Antibodies Market
30. Mexico Biosimilar Monoclonal Antibodies Market
31. Japan Biosimilar Monoclonal Antibodies Market
32. India Biosimilar Monoclonal Antibodies Market
33. United Kingdom Biosimilar Monoclonal Antibodies Market
34. France Biosimilar Monoclonal Antibodies Market
35. Italy Biosimilar Monoclonal Antibodies Market
36. Australia Biosimilar Monoclonal Antibodies Market
37. South Korea Biosimilar Monoclonal Antibodies Market
38. Russia Biosimilar Monoclonal Antibodies Market
39. Spain Biosimilar Monoclonal Antibodies Market
40. Competitive Landscape
40.1. Market Concentration Analysis, 2025
40.1.1. Concentration Ratio (CR)
40.1.2. Herfindahl Hirschman Index (HHI)
40.2. Recent Developments & Impact Analysis, 2025
40.3. Product Portfolio Analysis, 2025
40.4. Benchmarking Analysis, 2025
41. Company Profiles
41.1. Alvotech hf
41.2. Amgen Inc.
41.3. Aurobindo Pharma Ltd.
41.4. Bio-Thera Solutions, Ltd.
41.5. Biocon Ltd.
41.6. Boehringer Ingelheim International GmbH
41.7. Celltrion, Inc.
41.8. Coherus BioSciences, Inc.
41.9. Dr. Reddy's Laboratories Ltd.
41.10. Formycon AG
41.11. Fresenius Kabi AG
41.12. Intas Pharmaceuticals Ltd.
41.13. Lupin Ltd.
41.14. Mabwell Bioscience
41.15. Merck KGaA
41.16. Pfizer Inc.
41.17. Polpharma Biologics Group
41.18. Qilu Pharmaceutical Co., Ltd.
41.19. Reliance Life Sciences
41.20. Samsung Bioepis Co., Ltd.
41.21. Sandoz International GmbH
41.22. Shanghai Henlius Biotech, Inc.
41.23. Stada Arzneimittel AG
List of Figures
FIGURE 1. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2025 VS 2032 (%)
FIGURE 17. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
FIGURE 19. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
FIGURE 21. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
FIGURE 23. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 25. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 37. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. NATO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. NATO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. G7 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. G7 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. EUROPEAN UNION BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. EUROPEAN UNION BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. BRICS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. BRICS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. ASEAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. ASEAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. GCC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 49. GCC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 50. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 63. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 64. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL CHIMERIC MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL CHIMERIC MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL CHIMERIC MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL HUMANIZED MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL HUMANIZED MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL HUMANIZED MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ADALIMUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ADALIMUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ADALIMUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL INFLIXIMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL INFLIXIMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL INFLIXIMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL RITUXIMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL RITUXIMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL RITUXIMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL TRASTUZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL TRASTUZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL TRASTUZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL BEVACIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL BEVACIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL BEVACIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL RANIBIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL RANIBIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL RANIBIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL LIQUID SOLUTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL LIQUID SOLUTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL LIQUID SOLUTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL LYOPHILIZED POWDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL PREFILLED SYRINGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL PREFILLED SYRINGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL PREFILLED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL COMBINATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL IMMUNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL IMMUNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL IMMUNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL OPHTHALMOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL RHEUMATOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL RHEUMATOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL RHEUMATOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL AUTOIMMUNE & INFLAMMATORY DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL AUTOIMMUNE & INFLAMMATORY DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL AUTOIMMUNE & INFLAMMATORY DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 80. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 83. NORTH AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 84. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 86. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 87. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 88. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 89. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 90. EUROPE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 100. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 102. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 103. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 105. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 106. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 107. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 108. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 109. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 110. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 111. AFRICA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 112. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 114. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 115. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 116. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 117. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 118. MIDDLE EAST BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. NATO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 120. NATO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 121. NATO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 122. NATO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 123. NATO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 124. NATO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 125. NATO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 126. G7 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 127. G7 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 128. G7 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 129. G7 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 130. G7 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 131. G7 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 132. G7 BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 133. EUROPEAN UNION BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 134. EUROPEAN UNION BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 135. EUROPEAN UNION BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 136. EUROPEAN UNION BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 138. EUROPEAN UNION BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 139. EUROPEAN UNION BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 140. BRICS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 141. BRICS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 142. BRICS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 143. BRICS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 144. BRICS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 145. BRICS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 146. BRICS BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 147. ASEAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 148. ASEAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 149. ASEAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 150. ASEAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 151. ASEAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 152. ASEAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 153. ASEAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 154. GCC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 155. GCC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 156. GCC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 157. GCC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 158. GCC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 159. GCC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 160. GCC BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 161. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 162. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 163. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 164. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 165. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 166. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 167. UNITED STATES BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 168. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 169. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 170. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 171. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 172. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 173. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 174. CHINA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 175. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 176. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 177. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 178. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 179. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 180. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 181. CANADA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 182. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 183. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 184. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 185. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 186. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 187. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 188. GERMANY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 189. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 190. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 191. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 192. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 193. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 194. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 195. BRAZIL BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 196. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 197. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 198. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 199. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 200. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 201. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 202. MEXICO BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 203. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 204. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 205. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 206. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 207. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 208. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 209. JAPAN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 210. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 211. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 212. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 213. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 214. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 215. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 216. INDIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 217. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 218. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 219. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 220. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 221. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 222. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 223. UNITED KINGDOM BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 224. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 225. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 226. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 227. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 228. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 229. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 230. FRANCE BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 231. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 232. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 233. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 234. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 235. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 236. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 237. ITALY BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 238. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 239. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 240. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 241. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 242. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 243. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 244. AUSTRALIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 245. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 246. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 247. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 248. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 249. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 250. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 251. SOUTH KOREA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 252. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 253. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 254. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 255. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 256. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 257. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 258. RUSSIA BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 259. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 260. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY ANTIBODY CLASS, 2018-2032 (USD MILLION)
TABLE 261. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY MOLECULE CLASS, 2018-2032 (USD MILLION)
TABLE 262. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 263. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 264. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
TABLE 265. SPAIN BIOSIMILAR MONOCLONAL ANTIBODIES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Biosimilar Monoclonal Antibodies market report include:
  • Alvotech hf
  • Amgen Inc.
  • Aurobindo Pharma Ltd.
  • Bio-Thera Solutions, Ltd.
  • Biocon Ltd.
  • Boehringer Ingelheim International GmbH
  • Celltrion, Inc.
  • Coherus BioSciences, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Formycon AG
  • Fresenius Kabi AG
  • Intas Pharmaceuticals Ltd.
  • Lupin Ltd.
  • Mabwell Bioscience
  • Merck KGaA
  • Pfizer Inc.
  • Polpharma Biologics Group
  • Qilu Pharmaceutical Co., Ltd.
  • Reliance Life Sciences
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Shanghai Henlius Biotech, Inc.
  • Stada Arzneimittel AG

Table Information

Report AttributeDetails
No. of Pages197
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 9.91 Billion
Forecasted Market Value ( USD ) by 2032 $ 19.05 Billion
Compound Annual Growth Rate11.4%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Oncology Biosimilars Market by Product Type, Therapeutic Indication, Route of Administration, Patient Age Group, Distribution Channel - Global Forecast 2026-2032 - Product Image

Oncology Biosimilars Market by Product Type, Therapeutic Indication, Route of Administration, Patient Age Group, Distribution Channel - Global Forecast 2026-2032

  • Report
  • 199 Pages
  • Global
From
Psoriasis Biosimilar Market - Global Forecast 2026-2032 - Product Image

Psoriasis Biosimilar Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Biosimilar Monoclonal Antibodies Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Cancer Monoclonal Antibodies Market Size, Share, Trends and Forecast by Antibody Type, Medication Type, Application, End User, and Region, 2026-2034 - Product Image

Cancer Monoclonal Antibodies Market Size, Share, Trends and Forecast by Antibody Type, Medication Type, Application, End User, and Region, 2026-2034

  • Report
  • 136 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Market Report 2026 - Product Image

Biosimilar Monoclonal Antibodies Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Monoclonal Antibodies Market

Biosimilar Monoclonal Antibodies (mAbs) are biotechnological products that are similar to existing monoclonal antibodies (mAbs) that are already approved for use in humans. Biosimilar mAbs are developed using recombinant DNA technology and are designed to have the same structure and function as the original mAbs. Biosimilar mAbs are used to treat a variety of diseases, including cancer, autoimmune diseases, and infectious diseases. They are also used in research and development of new treatments. The biosimilar mAbs market is growing rapidly due to the increasing demand for mAbs in the treatment of various diseases. The market is expected to continue to grow as more mAbs are developed and approved for use in humans. Additionally, the increasing demand for mAbs in research and development is expected to drive the growth of the market. Some companies in the biosimilar mAbs market include Amgen, Biogen, Merck, Pfizer, and Novartis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.